Bafisontamab vs QLS5316

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR x c-MET · full Non-Small Cell Lung Cancer pipeline

Bafisontamab

Developed by Shanghai EpimAb Biotherapeutics

Phase 1/2 in Non-Small Cell Lung Cancerbispecific antibody
Weak signal

NCT03797391 · Phase 1/2 · status unknown

This was an open-label, non-randomized, single-arm dose-escalation and expansion study of EMB-01 in patients with advanced solid tumors, with no control group, so it cannot reliably show the drug's effect versus no treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Maximum tolerated dose (MTD) (phase 1 only) (cycle 1 (1cycle = 28 days)); Adverse Events (AEs), and Serious Adverse Events (SAEs) (Screening up to follow-up (30 days after the last dose)); Overall Response Rate (ORR) (phase 2 only) (From the date fo dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months): Phase I dose-escalation/expansion of EMB-01 (EGFR/cMET bispecific): 2 patients had a partial response (1 confirmed) and 14 had stable disease as best response; disease control rate 42.1%. 1600mg QW was determined as the RP2D (recommended phase 2 dose). (mixed)

Result source: NCT03797391

QLS5316

Developed by Qilu Pharmaceutical

Phase 1 in Non-Small Cell Lung Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07358884 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBafisontamabQLS5316
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
Duration of response, median—Not reported—Not reported

PFS, median

Bafisontamab
—Not reported
QLS5316
—Not reported

OS, median

Bafisontamab
—Not reported
QLS5316
—Not reported

ORR

Bafisontamab
—Not reported
QLS5316
—Not reported

Duration of response, median

Bafisontamab
—Not reported
QLS5316
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Bafisontamab: no structured comparison results are available for Non-Small Cell Lung Cancer.

QLS5316: no structured comparison results are available for Non-Small Cell Lung Cancer.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bafisontamab's landscape · QLS5316's landscape